In breast cancer cell models, bardoxolone methyl treatment led to significant depletion of phosphorylated LRP6 and phosphorylated Disheveled 2 (DVL2), alongside suppression of cytoplasmic β-catenin activation, resulting in the downregulation of Wnt target genes and cancer stem cell (CSC) markers [78]. This evidence concerns the gene LRP6 and breast cancer.